Welcome to our dedicated page for HCA Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Inc., a direct wholly owned subsidiary of HCA Healthcare, Inc., increased the maximum size of its commercial paper program on July 29, 2026. The program’s aggregate face or principal amount outstanding at any time was raised from $4.0 billion to $8.0 billion.
The unsecured commercial paper notes issued under this program are unconditionally guaranteed by HCA Healthcare, Inc., and all other terms of the program remain unchanged. The notes and related guarantee are not registered under the Securities Act of 1933 and may be offered or sold in the United States only pursuant to an applicable exemption.
HCA Healthcare reported solid growth for the quarter ended June 30, 2026. Revenue rose to $20,230 million, up 8.7% year over year, and net income attributable to HCA increased to $1,699 million, or $7.62 per diluted share, driven by higher revenue per equivalent admission and modest volume gains.
Results were heavily influenced by Medicaid programs. The quarter included $1,372 million of incremental revenue and $829 million of other operating expenses from Florida’s directed payment program, producing about $400 million of incremental net benefit. At the same time, expiration of enhanced premium tax credits contributed to higher uninsured admissions and pushed total uncompensated care for the quarter to $15.076 billion.
Operating cash flow for the first six months fell to $4,349 million from $5,861 million, mainly due to working-capital effects from Medicaid state directed and supplemental payment programs and a $594 million increase in income tax payments. HCA continued returning capital, repurchasing 7.909 million shares at an average price of $447.53 and ending with $7.210 billion of remaining repurchase authorization, while total debt increased to $49,718 million.
HCA Healthcare reported solid second quarter 2026 results with revenues of $20.230 billion, up 8.7% from a year earlier. Net income attributable to HCA was $1.699 billion and diluted EPS rose to $7.62 (adjusted EPS $7.59). Adjusted EBITDA increased to $4.027 billion, while same facility admissions grew 2.5%, equivalent admissions 2.7% and emergency room visits 3.6%. Same facility inpatient and outpatient surgeries declined 2.3% and 3.4%, respectively.
Results reflected a payer mix shift from higher uninsured volume tied to health insurance exchanges, which HCA estimates reduced income before income taxes by about $400 million in the quarter. This was partly offset by approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, largely from a Florida directed payment program that added $1.372 billion of revenues and $829 million of other operating expenses for periods back to October 1, 2024.
For the first six months of 2026, revenues were $39.339 billion and net income attributable to HCA was $3.319 billion (EPS $14.77). As of June 30, 2026 HCA held $1.013 billion in cash, $49.718 billion of total debt and $63.250 billion of total assets. Operating cash flow for the quarter was $2.335 billion. Capital expenditures in the quarter were $1.231 billion, and HCA repurchased 4.752 million shares for $2.064 billion, leaving $7.210 billion under its authorization. The board declared a quarterly cash dividend of $0.78 per share, payable September 30, 2026.
HCA updated its 2026 outlook, now guiding to revenues of $77.000 to $79.500 billion, net income attributable to HCA of $6.300 to $6.700 billion, Adjusted EBITDA of $15.400 to $16.100 billion, and diluted EPS of $28.70 to $30.50. The company raised its estimated unfavorable impact from health insurance exchanges on 2026 income before income taxes to $(1.000) to $(1.200) billion, from $(600) to $(900) million, and increased its expected Medicaid Supplemental Payment Programs net benefit to $300 to $500 million, from a prior estimate of $(50) to $(250) million. The 2026 capital expenditure estimate of $5.0 to $5.5 billion, excluding acquisitions, remains unchanged.
HCA Healthcare released preliminary second-quarter 2026 results and reduced its 2026 outlook. Q2 revenues are expected at $20.230 billion, up from $18.605 billion a year earlier. Net income attributable to HCA is estimated at $1.699 billion, or $7.62 per diluted share, versus $1.653 billion, or $6.83 per share. Adjusted EBITDA is projected at $4.027 billion, compared with $3.849 billion.
Operationally, same-facility admissions and equivalent admissions grew 2.5% and 2.7%, and emergency room visits rose 3.6%, while inpatient and outpatient surgeries declined 2.3% and 3.4%. Management estimates a payer mix shift toward more uninsured patients reduced income before income taxes by about $400 million, partially offset by roughly $400 million of incremental net benefit from Medicaid Supplemental Payment Programs, mainly in Florida.
For 2026, HCA now guides to revenues of $77.0–$79.5 billion, net income of $6.3–$6.7 billion, Adjusted EBITDA of $15.4–$16.1 billion, and diluted EPS of $28.70–$30.50, all lower than prior ranges, while keeping capital expenditures at $5.0–$5.5 billion.
HCA Healthcare, Inc. announced that Dr. Michael Cuffe, its Executive Vice President and Chief Clinical Officer, will step down from his role effective August 31, 2026.
He will remain with the company in a transitional role until February 2027 and will be eligible for benefits under HCA Healthcare’s executive severance policy and applicable incentive plans.
HCA Healthcare EVP and CFO Mike A. Marks reported gifting shares of the company’s common stock. On May 7, 2026, he made two bona fide gift transfers totaling 6,672 shares, one from direct holdings and one from an indirect trust holding.
After these gifts, direct ownership fell to 0 shares, while indirect ownership continued through family trusts. One holding entry shows 26,500 shares held indirectly by the LAM 2020 Trust, and another shows 46,576 shares held indirectly by the MAM 2020 Trust following the reported transactions.
Frist William R reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare, Inc. director and ten percent owner William R. Frist reported an equity award tied to his board service. He received 809 restricted share units at no cost, comprising 509 units from an annual director equity award and 300 units elected in lieu of a cash retainer.
The restricted share units vest on the earlier of the 2027 annual shareholders’ meeting or the first anniversary of the grant, with shares delivered when he leaves the board. After this award, he directly holds 13,740 shares and has significant indirect interests through entities including Frisco Holding II, which holds 36,557,141 shares, and Hercules Holding II, which holds 32,282,889 shares, where he may be deemed to share voting and investment control but disclaims beneficial ownership beyond his pecuniary interests.
FRIST THOMAS F III reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare director Thomas F. Frist III reported a grant of 1,041 shares of common stock in the form of restricted share units. These units reflect an annual director equity award and amounts received instead of cash retainers for his service as a director and as Chairman of the Board.
The award consists of 509 restricted share units from an annual director equity grant and 532 restricted share units received in lieu of cash retainers. These units will vest on the earlier of the 2027 annual shareholders' meeting or the first anniversary of the grant date, and vested shares will be delivered when he ceases to serve on the Board. Following this grant, he directly holds 15,858 shares, alongside large indirect holdings through Hercules Holding II and Frisco Holding II.
Smith Andrea B reported acquisition or exercise transactions in this Form 4 filing.
HCA Healthcare, Inc. director Andrea B. Smith reported receiving an equity-based compensation award in the form of 509 restricted share units of common stock. These units are part of an annual director equity award and carry a grant price of $0.00 per share, reflecting compensation rather than a market purchase.
The award will vest on the earlier of the company’s 2027 annual shareholders’ meeting or the first anniversary of the grant date. Vested shares will be delivered when she ceases to serve on HCA’s Board of Directors. Following this grant, she directly holds 4,666 shares of common stock.
Separately, 82 shares are reported as held in fully managed accounts over which Smith has no investment authority. She disclaims beneficial ownership of those managed-account shares except to the extent of her pecuniary interest.
HCA Healthcare director Wayne Joseph Riley received an equity grant of 509 restricted share units of common stock. The award is described as an annual director equity grant and carries no cash exercise price. Following this grant, he directly holds 15,029 shares of HCA Healthcare common stock.
The 509 restricted share units will vest on the earlier of HCA Healthcare’s 2027 annual shareholders’ meeting or the first anniversary of the grant date. According to the terms, the vested shares will be delivered to Riley when he ceases to serve on the company’s Board of Directors.